[go: up one dir, main page]

EA202191771A1 - RNAi-BASED COMPOSITIONS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS OF THEIR APPLICATION - Google Patents

RNAi-BASED COMPOSITIONS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS OF THEIR APPLICATION

Info

Publication number
EA202191771A1
EA202191771A1 EA202191771A EA202191771A EA202191771A1 EA 202191771 A1 EA202191771 A1 EA 202191771A1 EA 202191771 A EA202191771 A EA 202191771A EA 202191771 A EA202191771 A EA 202191771A EA 202191771 A1 EA202191771 A1 EA 202191771A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hbv
methods
virus
rnai
application
Prior art date
Application number
EA202191771A
Other languages
Russian (ru)
Inventor
Грегори Хинкл
Лаура Сепп-Лорензино
Васант Джадхав
Мартин Майер
Стюарт Милстейн
Мутхиах Манохаран
Каллантхоттатхил Г. Раджив
Original Assignee
Элнилэм Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элнилэм Фармасьютикалз, Инк. filed Critical Элнилэм Фармасьютикалз, Инк.
Publication of EA202191771A1 publication Critical patent/EA202191771A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к средствам для RNAi, например двухнитевым средствам для RNAi, целенаправленно воздействующим на геном вируса гепатита B (HBV), к способам применения таких средств для RNAi для ингибирования экспрессии одного или нескольких генов HBV и к способам лечения субъектов с инфекцией HBV и/или ассоциированным с HBV нарушением, например хронической инфекцией, вызванной вирусом гепатита B.The invention relates to RNAi agents, such as double-stranded RNAi agents that target the hepatitis B virus (HBV) genome, to methods for using such RNAi agents to inhibit the expression of one or more HBV genes, and to methods for treating subjects with HBV infection and/or an HBV-associated disorder, such as chronic hepatitis B virus infection.

EA202191771A 2015-03-24 2015-11-10 RNAi-BASED COMPOSITIONS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS OF THEIR APPLICATION EA202191771A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562137464P 2015-03-24 2015-03-24

Publications (1)

Publication Number Publication Date
EA202191771A1 true EA202191771A1 (en) 2022-01-31

Family

ID=80631230

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202191771A EA202191771A1 (en) 2015-03-24 2015-11-10 RNAi-BASED COMPOSITIONS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS OF THEIR APPLICATION
EA201791014A EA039127B1 (en) 2015-03-24 2015-11-10 HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201791014A EA039127B1 (en) 2015-03-24 2015-11-10 HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Country Status (1)

Country Link
EA (2) EA202191771A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202114731A (en) * 2019-06-18 2021-04-16 愛爾蘭商健生科學愛爾蘭無限公司 COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067249B2 (en) * 2003-05-19 2006-06-27 The University Of Hong Kong Inhibition of hepatitis B virus (HBV) replication by RNA interference
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
CN101314047A (en) * 2007-06-01 2008-12-03 中国科学院微生物研究所 Method and medicine for treating viral infection
CN103275971A (en) * 2008-06-13 2013-09-04 厦门大学 RNA interference targets for hepatitis b virus (HBV) infection treatment
EP4079856A1 (en) * 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
UA118951C2 (en) * 2011-04-21 2019-04-10 Айоніс Фармасьютікалз, Інк. MODULATION OF HEPATITIS B (HBV) VIRUS EXPRESSION
CN103014045B (en) * 2012-12-30 2014-09-17 中国人民解放军第三军医大学 Recombinant HBV (Hepatitis B Virus) vector for expressing specific HBVshRNA (Hepatitis B Virus Short Hairpin Ribonucleic Acid) as well as construction method and application of vector

Also Published As

Publication number Publication date
EA201791014A1 (en) 2017-10-31
EA039127B1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
MX2021006635A (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof.
PH12021550287A1 (en) HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
CO2018006590A2 (en) Methods and compositions for the treatment of a disorder associated with serpinc1
EA201791460A1 (en) N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
EA201691726A1 (en) NEW 6-CONDENSED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
BR112017013028A2 (en) nucleosides, nucleotides and analogs thereof substituted
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
EA201691261A1 (en) NEW DIHYDROCHINOLYSINES FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY THE HEPATITIS B VIRUS
HK1244843A1 (en) Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
PH12017500614A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
EA201891532A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF HEMOGLOBINOPATHY
EA201890736A1 (en) Modulators of the cow protein of the hepatitis B virus
MX2021006053A (en) ANGIOTENSINOGEN (AGT) ARNI COMPOSITIONS AND METHODS OF USE THEREOF.
EA201692537A1 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES
EA201890454A1 (en) PYRROPHYRIMIDINE NUCLEOSIDE AND THEIR ANALOGUES THAT CAN BE USED AS ANTI-VIRUS MEANS
EA201790789A1 (en) COMPOSITIONS AND METHODS DESIGNED TO INHIBIT EXPRESSION OF THE HAO1 GENE (OXIDASE 1 HYDROXYLIC ACIDS (GLYCOLATE OXIDASE))
PL3684377T3 (en) WAYS TO TREAT HEPATITIS B VIRUS INFECTION
EA201692473A1 (en) METHODS OF OBTAINING SUBSTITUTED NUCLEOTIDE ANALOGS
EA201790160A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY VIRUSES HEPATITIS B AND HEPATITIS D
EA201891666A1 (en) ARYL SUBSTITUTE PYRIMIDINES FOR APPLICATION IN INFECTION CAUSED BY THE VIRUS VIRUS
EA201690685A1 (en) COMPOSITIONS AND METHODS OF INHIBITING THE EXPRESSION OF THE ALAS1 GENE
HK1251010A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EP3370723A4 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
EA201892448A1 (en) ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
EA202191771A1 (en) RNAi-BASED COMPOSITIONS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS OF THEIR APPLICATION